Systems Biology of E2F Signaling in Tumor Progression and Metastasis (SysMet)

Systems Biology of E2F Signaling in Tumor Progression and Metastasis (SysMet)

This project is to generate and analyze a computational multilevel model of a signaling network that has a key role in tumor progression and metastasis. The project brings together an experienced group of modelers with an internationally renowned group in cancer research with a leading role on E2F1 signaling, investigating for the first time the impact of E2F1 on cancer aggressiveness using a systems approach.

Existing clinical evidence is sparse and available datasets are only qualitative. This project is to develop and use a novel systems approach which integrates existing data with new experiments to iteratively derive a quantitative model that allows therapeutic predictions after pre-clinical evaluations. This is the first time that computational modeling, cell culture experiments, patient data and functional in vivo testing are combined in one project to unravel the role of E2F1 in tumor progression and metastasis.

The interdisciplinary collaboration, combining data-driven modeling and model-driven experimentation, allows a direct translation of basic cancer research into a clinical application for the development of novel anti-metastatic therapeutics.

Related publications

LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1

Logotheti S, Marquardt S, Gupta SK, Richter C, Edelhäuser BAH, Engelmann D, Brenmoehl J, Söhnchen C, Murr N, Alpers M, Singh KP, Wolkenhauer O, Heckl D, Spitschak A, Pützer BM

Theranostics 2020; 10(21):9620-9643.

An integrative network-driven pipeline for systematic identification of lncRNA-associated regulatory network motifs in metastatic melanoma

Singh N, Eberhardt M, Wolkenhauer O, Vera J, Gupta SK

BMC Bioinformatics 2020, 21 (1), 1-17

Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic Cancers.

Goody D, Gupta SK, Engelmann D, Spitschak A, Marquardt S, Mikkat S, Meier C, Hauser C, Gundlach JP, Egberts JH, Martin H, Schumacher T, Trauzold A, Wolkenhauer O, Logotheti S, Pützer BM.

Theranostics. 2019 Feb 20;9(5):1490-1509.